[Progress in chimeric antigen receptor NK cell therapy for hematological malignancies].
作者信息
Wang X D, Mei H, Hu Y
机构信息
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Dec 14;43(12):1051-1056. doi: 10.3760/cma.j.issn.0253-2727.2022.12.015.
Abstract
摘要
相似文献
1
[Progress in chimeric antigen receptor NK cell therapy for hematological malignancies].[嵌合抗原受体自然杀伤细胞治疗血液系统恶性肿瘤的研究进展]
Zhonghua Xue Ye Xue Za Zhi. 2022 Dec 14;43(12):1051-1056. doi: 10.3760/cma.j.issn.0253-2727.2022.12.015.
2
Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.嵌合抗原受体自然杀伤细胞疗法在克服难治性血液系统恶性肿瘤方面的最新进展。
Hematol Oncol. 2021 Feb;39(1):11-19. doi: 10.1002/hon.2802. Epub 2020 Sep 21.
3
CAR-NK cell in cancer immunotherapy; A promising frontier.嵌合抗原受体自然杀伤（CAR-NK）细胞在癌症免疫治疗中的应用：一个充满希望的前沿领域。
Cancer Sci. 2021 Sep;112(9):3427-3436. doi: 10.1111/cas.14993. Epub 2021 Jul 7.
4
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.嵌合抗原受体自然杀伤细胞（CAR-NK）用于肿瘤免疫治疗：临床转化与未来前景。
Cancer Lett. 2020 Mar 1;472:175-180. doi: 10.1016/j.canlet.2019.11.033. Epub 2019 Nov 29.
5
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.嵌合抗原受体自然杀伤细胞疗法治疗血液系统恶性肿瘤：2022 年ASH 年会最新进展。
J Hematol Oncol. 2023 Apr 7;16(1):35. doi: 10.1186/s13045-023-01435-3.
6
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.嵌合抗原受体自然杀伤细胞疗法治疗恶性肿瘤的临床前和临床研究。
Front Immunol. 2022 Oct 24;13:992232. doi: 10.3389/fimmu.2022.992232. eCollection 2022.
7
[The current status and optimization strategies of CAR-T cell therapy in hematological malignancies].[嵌合抗原受体T细胞疗法在血液系统恶性肿瘤中的现状及优化策略]
Zhonghua Nei Ke Za Zhi. 2023 Jun 1;62(6):581-586. doi: 10.3760/cma.j.cn112138-20230410-00191.
8
[Chimeric antigen receptor T cells for hematological malignancies: current understanding and future challenge].[用于血液系统恶性肿瘤的嵌合抗原受体T细胞：当前认识与未来挑战]
Zhonghua Nei Ke Za Zhi. 2019 Nov 1;58(11):793-795. doi: 10.3760/cma.j.issn.0578-1426.2019.11.001.
9
Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies.嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的早期血细胞减少和感染
Leuk Lymphoma. 2023 Sep;64(9):1592-1595. doi: 10.1080/10428194.2023.2220455. Epub 2023 Jun 7.
10
CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.嵌合抗原受体自然杀伤（CAR-NK）细胞疗法在血液系统恶性肿瘤和实体瘤中的应用；克服挑战的障碍和策略。
Int Immunopharmacol. 2022 Sep;110:109041. doi: 10.1016/j.intimp.2022.109041. Epub 2022 Jul 12.
引用本文的文献
1
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.嵌合抗原受体自然杀伤细胞：一种有前景的抗肿瘤免疫疗法。
MedComm (2020). 2023 Dec 1;4(6):e422. doi: 10.1002/mco2.422. eCollection 2023 Dec.
本文引用的文献
1
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.CXCR4 和抗 BCMA CAR 共修饰的自然杀伤细胞在异种移植小鼠模型中抑制多发性骨髓瘤的进展。
Cancer Gene Ther. 2022 May;29(5):475-483. doi: 10.1038/s41417-021-00365-x. Epub 2021 Sep 1.
2
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.NKG2D-CAR 修饰的自然杀伤细胞能有效靶向多发性骨髓瘤。
Blood Cancer J. 2021 Aug 14;11(8):146. doi: 10.1038/s41408-021-00537-w.
3
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.嵌合抗原受体自然杀伤 (CAR-NK) 细胞设计与工程在癌症治疗中的应用。
J Hematol Oncol. 2021 May 1;14(1):73. doi: 10.1186/s13045-021-01083-5.
4
Metabolic changes of Interleukin-12/15/18-stimulated human NK cells.白细胞介素-12/15/18 刺激的人自然杀伤细胞的代谢变化。
Sci Rep. 2021 Mar 19;11(1):6472. doi: 10.1038/s41598-021-85960-6.
5
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.表达亲和力优化的 CD38 嵌合抗原受体的 CD38 敲除自然杀伤细胞成功靶向急性髓细胞白血病，减少效应细胞自噬。
Haematologica. 2022 Feb 1;107(2):437-445. doi: 10.3324/haematol.2020.271908.
6
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas.分析肿瘤浸润 NK 和 T 细胞突出了 IL-15 刺激和 TIGIT 阻断作为软组织肉瘤的联合免疫治疗策略。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001355.
7
Exploring the NK cell platform for cancer immunotherapy.探索自然杀伤细胞平台在癌症免疫疗法中的应用。
Nat Rev Clin Oncol. 2021 Feb;18(2):85-100. doi: 10.1038/s41571-020-0426-7. Epub 2020 Sep 15.
8
Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes.NK细胞和T细胞中TIGIT的过表达导致骨髓增生异常综合征的肿瘤免疫逃逸。
Front Oncol. 2020 Aug 7;10:1595. doi: 10.3389/fonc.2020.01595. eCollection 2020.
9
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.靶向细胞因子检查点增强了装甲脐血 CAR-NK 细胞的适应性。
Blood. 2021 Feb 4;137(5):624-636. doi: 10.1182/blood.2020007748.
10
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia.供体记忆样自然杀伤细胞的多维分析揭示了与白血病过继免疫治疗后反应的新关联。
Cancer Discov. 2020 Dec;10(12):1854-1871. doi: 10.1158/2159-8290.CD-20-0312. Epub 2020 Aug 21.
Zotero 插件